Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(22 sites)

United States

Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois

Dana-Farber Cancer Institute and Boston Children's Hospital, Boston, Massachusetts

Helen DeVos Children's Hospital, Grand Rapids, Michigan

Dell Children's Medical Group SFC-HEM/ONC, Austin, Texas

Austria

Medical University of Graz, Graz

Medical University of Innsbruck, Innsbruck

Kepler Universitätsklinikum Med Campus IV, Linz

Salzburger Universitätsklinikum, Salzburg

Medical University of Vienna, Vienna

Czechia

University Hospital Brno, Brno

Motol University Hospital Prague, Prague

Denmark

University hospital Rigshospitalet, Copenhagen

France

Centre Oscar Lambret, Lille

Centre Léon Bérard, Lyon

Norway

Onkologisk-hematologisk seksjon Barneklinikken Haukeland universitetssjukehus, Bergen

Spain

Hospital Infantil Universitario Nino Jesus, Madrid

Sweden

Sahlgrenska Universitetssjukhuset, Gothenburg

Universitetssjukhuset Linköping, Linköping

Skånes universitetssjukhus, Lund

Karolinska University Hospital, Stockholm

Norrlands Universitetssjukhus, Umeå

Akademiska sjukhuset, Uppsala